The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly

Journal of Postgraduate Medicine

Volumn 56, Issue 1, 2010, Pages 7-11

  Bandgar, T R ^a   Sarathi, V ^a   Shivane, V ^a   Bansode, N ^a   Menon, P S ^a   Shah, N S ^a  

^a KEM HOSPITAL   (India)

Author keywords

Acromegaly; Octreotide suppression test; Octreotide test dose; Remission prediction; Somatostatin analogue

Indexed keywords

GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; INDIA; MALE; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; REMISSION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ACROMEGALY; ADULT; AGED; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INDIA; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77951684436     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.62421     Document Type: Article

References (14)

1. Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S. Outcome of surgery for acromegaly performed by different surgeons: Importance of surgical experience. Pituitary 2005;8:93-7.
2. Gilbert JA, Miell J P, Chambers SM, McGregor AM, Aylwin SJ. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf) 2005;62:742-7.
3. Lindsay JR, McConnell EM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary 2004;7:139-44.
4. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res 2005;15:200-6.
5. Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, et al. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res 2008;40:422-6.
6. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996;81:2356-62.
7. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 2005;153:67-71.
8. Pokrajac A, Claridge AG, Shakoor SK, Trainer PJ. The octreotide test dose is not a reliable predictor of subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 2006;154:267-74.
9. Melmed S, Casanueva F F, Cavagnini F, Chanson P, Frohman L, Grossman A, et al. Acromegaly Treatment Consensus Workshop Participants: Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.
10. Aylwin S. Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' GH levels. Clin Endocrinol (Oxf) 2006;65:133.
11. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA. The value of an octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 2005;62:282-8.
12. Monson J P. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology 2006;83:269-73.
13. Halah F P, Elias LL, Martinelli CE Jr, Castro M, Moreira AC. Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly. Arq Bras Endocrinol Metabol 2004;48:245-52.
14. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001;86:1645-52.